Join to access to all OVN content. Join Now

Results for 'trastuzumab'

...
OVN Avatar Ali Raza Khaki
Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Dec 1st • 4 mins read

...
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Nov 20th • 12 mins read

...
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes
Leveraging existing data to contextualize phase II clinical trial findings in oncology

Sep 21st • 3 mins read

...
OVN Avatar Mark Verrill, Paul Declerck, Sibylle Loibl, Jake Lee & Javier Cortes
The rise of oncology biosimilars: from process to promise

Aug 23rd • 18 mins read

...
OVN Avatar Gregory S. Calip, PharmD, MPH, PhD, Ivy P. Altomare, MD, Jenny S. Guadamuz, MSPH, PhD
Evaluating External Validity of Oncology Biosimilar Safety Studies

Apr 6th • 2 mins read

...
OVN Avatar Laleh Amiri-Kordestani & Richard Pazdur
Oncology approvals in 2020: a year of firsts in the midst of a pandemic

Jan 29th • 4 mins read

...
OVN Avatar Chad Williamson, MBA, MS Leanne Berger, BS, Thomas P. Sullivan, BS SHOW
Addressing oncologists' gaps in the use of biosimilar products

Jun 19th • 5 mins read

...
OVN Avatar Steven Sorscher
Clinical Trials in Oncology and Defining Benefit

Jan 22nd • 1 min read